Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus lomustine versus lomustine alone in first recurrent glioblastoma
2010-023218-30Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Bevacizumab plus lomustine with Lomustine alone (2 arms). Primary endpoint: Overall survival. Started Jun 2011; status: completed.
02
Drugs
bevacizumablomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2010-023218-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023218-30.